pharma · Alopecia areata · Multiple myeloma
First Biotech (Australia)
Pfizer Australia Pty Ltd
Pfizer Australia Pty is a pharma organization headquartered in AU. Primary therapeutic focus areas include Alopecia areata, Multiple myeloma, Heart failure, Acute Migraine (with or without aura), Transthyretin amyloidosi
Company details
- Status
- Public
- HQ
- Norwest House, 710 Collins Street, Melbourne, VIC 3008, AU
- Founded
- 2017
- Employees
- 2
- Programs
- 126
- Drugs
- 208
- Patents
- 0
LETROZOLE, FULVESTRANT
Phase 2 · small molecule · Part 2A, 2B, 2C & 2E HR-positive /HER2-negative breast cancer, Part 1F Prostate cancer, Part 2D mCRPC, Part 1A/Part 1D/Part1E Breast cancer, NSCLC, prostate, CRC, liposarcoma, or tumors with previously confirmed CDK4 or CCND1 amplification., Part 1B &1C HR-positive/HER2-negative breast cancer
LETROZOLE, FULVESTRANT for Part 2A, 2B, 2C & 2E HR-positive /HER2-negative breast cancer, Part 1F Prostate cancer, Part 2D mCRPC, Part 1A/Part 1D/Part1E Breast cancer, NSCLC, prostate, CRC, liposarcoma, or tumors with previously confirmed CDK4 or CCND1 amplification., Part 1B &1C HR-positive/HER2-negative breast cancer is a Phase 2 program (small_molecule) at Pfizer Australia Pty Ltd with 1 ClinicalTrials.gov record(s).
Internal code C4391001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pfizer Australia Pty Ltd
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Part 2A, 2B, 2C & 2E HR-positive /HER2-negative breast cancer, Part 1F Prostate cancer, Part 2D mCRPC, Part 1A/Part 1D/Part1E Breast cancer, NSCLC, prostate, CRC, liposarcoma, or tumors with previously confirmed CDK4 or CCND1 amplification., Part 1B &1C HR-positive/HER2-negative breast cancer
- Status
- active
- Trials
- 1